News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Novo Nordisk is set to acquire three manufacturing facilities from contract development and manufacturing organization Catalent, in a bold move that has sparked a great deal of debate and some backlash.
In a recent quarterly update, AstraZeneca revealed that it removed tozorakimab from its phase 2 pipeline for diabetic kidney disease (DKD).
QBiotics’ lead intratumoural oncology asset, tigilanol tiglate, has been awarded Orphan Drug Designation for the treatment of soft tissue sarcoma (STS) by the United States Food and Drug Administration (FDA).